BRCA

  • July 28, 2021  

    ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark

    George Lundberg, MD

    As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.

    .

  • February 2, 2021  

    How an Expert Would Manage Her Own Advanced Ovarian Cancer

    With: Summer Dewdney, MD

    Cancer patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Summer Dewdney, MD, how she would handle her own diagnosis of advanced ovarian cancer. Dr. Dewdney is Director of the Division of Gynecologic Oncology at Rush University Medical Center in Chicago, Illinois. Curious Dr. George: You are an expert clinical oncologist treating patients… Read more »

  • May 12, 2020  

    Pancreatic Cancer Survival Rates: What Do They Really Mean?

    Lola Rahib, PhD

    The American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic cancer is the same. Understanding what survival rates mean—and which factors can impact them—could help you navigate your or your loved one’s disease. What is the five-year relative survival rate for pancreatic cancer? In… Read more »

  • February 22, 2020  

    ‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Bookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 13, 2019  

    Serious Caveats in Screening for Pancreatic Cancer

    With: Rama Gullapalli, MD, PhD

    A Q&A with Rama Gullapalli, MD, PhD; a physician-scientist in the departments of Pathology, Chemical and Biological Engineering at the University of New Mexico. His research lab focuses on the role of the environment in hepatobiliary cancers. He is also a practicing molecular pathologist with an interest in emerging molecular diagnostics, next generation sequencing and bioinformatics. Email: rgullapalli@salud.unm.edu  Q: A recent New York Times… Read more »

  • August 22, 2018  

    PARP Inhibitor Talazoparib Benefit in BCRA+ Breast Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt from Medscape:

    “The now-published results from the EMBRACA study confirm that  talazoparib (Pfizer), a poly-adenosine diphosphate-ribose polymerase (PARP) inhibitor,  prolongs progression-free survival (PFS) in patients with advanced BCRA-positive breast cancer compared with single-agent chemotherapy alone, and that it also significantly improves quality of life.

    ” ‘This is the largest randomized trial in BRCA mutation carriers [ever undertaken] and demonstrates PARP efficacy,’ Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, told Medscape Medical News in an email.”

    Go to full article published by Medscape on Aug 15, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.